HeartBeat.bio AG

HeartBeat.bio is a pioneering TechBio company leveraging a next-generation drug discovery platform to develop breakthrough medicines for heart failure patients. Heart failure is a rapidly growing global health crisis, affecting over 30 million people in major pharmaceutical markets, with limited treatment options. Despite its prevalence, innovation in this space has lagged—creating a massive opportunity for disruption. Our proprietary Cardioid Drug Discovery Platform integrates iPSC-derived cardiac organoids with AI-driven analytics and advanced automation. Unlike traditional drug discovery, which relies heavily on animal models with poor clinical translatability, our human-centric approach enables more predictive, efficient, and cost-effective drug development. By combining physiologically relevant human models with cutting-edge technology, we aim to accelerate drug discovery, reduce failure rates, and bring novel therapies to patients faster. We are advancing our own pipeline while strategically partnering with pharma and biotech companies to co-develop transformative heart failure treatments. Recently, we closed our first longer-term partnership deal with a leading player in cardiovascular disease. Initial focus areas include cardiomyopathies, myocardial fibrosis, and cardiac remodeling—high-impact indications with significant unmet needs.